<DOC>
	<DOCNO>NCT02155192</DOCNO>
	<brief_summary>The purpose study evaluate association genetic factor response treatment ( guselkumab , ustekinumab , adalimumab , etanercept ) psoriasis ( scaly skin rash ) .</brief_summary>
	<brief_title>An Exploratory Genetic Study Participants With Psoriasis</brief_title>
	<detailed_description>This Phase 0 , exploratory ( intend conduct early Phase 1 , involve limited human exposure , therapeutic intent intend examine clinical tolerability ) , multicenter ( one hospital medical school team work medical research study ) pharmacogenomics study participant psoriasis . Participants treat study Phase 2 NCT01483599 ( X-PLORE ) , Phase 3 NCT00267969 ( PHOENIX 1 ) , Phase 3 NCT00307437 ( PHOENIX 2 ) Phase 3 NCT00454584 ( ACCEPT ) , return study site deoxyribonucleic acid ( DNA ) sample obtain pharmacogenomics assessment . There follow-up beyond study site visit .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Participants must randomly assign treated NCT01483599 ( XPLORE ) , NCT00267969 ( PHOENIX 1 ) , NCT00307437 ( PHOENIX2 ) , NCT00454584 ( ACCEPT ) study Sign inform consent document indicate understand purpose procedure require study willing participate study Participants condition , opinion investigator , participation would best interest subject ( example , compromise wellbeing ) could prevent , limit , confound protocolspecified assessment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>CNTO1959PSO2001</keyword>
	<keyword>C0743T08</keyword>
	<keyword>C0743T09</keyword>
	<keyword>C0743T12</keyword>
	<keyword>Psoriasis</keyword>
	<keyword>Pharmacogenomics</keyword>
</DOC>